Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 4/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.45 |
| ▸ | XDH | P47989 | 2/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 6/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.36 |
| ▸ | PRKDC | P78527 | 4/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1741651 | 0.98 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Hydrochloric Acid SCHEMBL14742344 | 0.98 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Aminacrine SCHEMBL1342785 | 0.81 | KDM4E (0.51) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Allopurinol SCHEMBL4916844 | 0.80 | RET (0.57) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Ribose (Furanose) SCHEMBL4083364 | 0.77 | HIF1A (0.47) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL1128530 | 0.74 | PDE4A (0.38) | CHEK1AURKADYRK1A | |
| SCHEMBL4975500 | 0.74 | — | — | |
| Tisopurine SCHEMBL7160585 | 0.74 | — | — | |
| Allopurinol SCHEMBL2563567 | 0.72 | CCNE2 (0.30) | — | |
| SCHEMBL13369828 | 0.71 | CCNE2 (0.35) | CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 986 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | claimed |
| CN-117820320-A | Preparation method of heat-resistant energetic material PTO | 南京理工大学 | 2024-04-05 | — | — | CN | claimed |
| US-20230365570-A1 | COMPOUNDS WITH GLUCOCORTICOID SPARING EFFECTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | claimed |
| US-11786528-B2 | Pyrazolopyrimidine compounds as adenosine receptor antagonists | EXSCIENTIA LTD. (GB) | 2023-10-17 | — | — | US | claimed |
| WO-2022268148-A1 | COMPOUND FOR DEGRADING BTK PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 天津医科大学肿瘤医院 | 2022-12-29 | — | — | WO | claimed |
| CN-113264937-B | 4-aminopyrazolo [3,4-d ] pyrimidine derivative and application thereof | 南开大学 | 2022-11-29 | — | — | CN | claimed |
| US-20220195497-A1 | HYBRIDIZING all-LNA OLIGONUCLEOTIDES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2022-06-23 | — | — | US | claimed |
| EP-3442535-B1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-06-01 | — | — | EP | claimed |
| WO-2022076473-A1 | COMPOUNDS WITH GLUCOCORTICOID SPARING EFFECTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-14 | — | — | WO | claimed |
| EP-3980554-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | claimed |
| US-20030118999-A1 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2003-06-26 | — | — | US | claimed |
| EP-1308452-A2 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2003-05-07 | — | — | EP | claimed |
| US-6486308-B2 | NUCLEOTIDE SEQUENCE BINDING PARTICLES; FOR USE AS THERAPEUTIC AND DIAGNOSTIC TOOLS | EPOCH BIOSCIENCES, INC. | 2002-11-26 | — | — | US | claimed |
| US-20020052482-A1 | Covalently linked oligonucleotide minor grove binder conjugates | MICROPROBE | 2002-05-02 | — | — | US | claimed |
| EP-0503700-B1 | Method for the preparation of iodobromide emulsions containing monodisperse tabular grains | AGFA GEVAERT NV (BE) | 1996-10-16 | — | — | EP | claimed |
| US-5385818-A | Process for the preparation of silver halide emulsions and photographic elements containing hollow silver halide grains | EASTMAN KODAK COMPANY (US) | 1995-01-31 | — | — | US | claimed |
| EP-0231605-B1 | RIBOFLAVIN PRODUCTION WITH YEAST | ZeaGen, Inc. (US) | 1993-04-07 | — | — | EP | claimed |
| EP-0503700-A1 | Method for the preparation of iodobromide emulsions containing monodisperse tabular grains | AGFA-GEVAERT N.V. (BE) | 1992-09-16 | — | — | EP | claimed |
| EP-0231605-A2 | Riboflavin production with yeast | ZeaGen, Inc. (US) | 1987-08-12 | — | — | EP | claimed |
| US-4267324-A | BY REACTION OF FORMAMIDINE AND 3-AMINO-4-CYANOPYRAZOLE | POLAROID CORPORATION (US) | 1981-05-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052482-A1 | Covalently linked oligonucleotide minor grove binder conjugates | CD2BP2, MICA, SELPLG | PI4KA 4632/4885PI4K2B 4426/4885PI4K2A 4601/4885 |
| US-11786528-B2 | Pyrazolopyrimidine compounds as adenosine receptor antagonists | ADORA1, ADORA3, ADORA2A | PI4KA 867/4885PI4K2B 1664/4885PI4K2A 1618/4885 |
| US-20030118999-A1 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | PCNA, DUT, POLL | PI4KA 1267/4885PI4K2B 1295/4885PI4K2A 1183/4885 |
| US-20230365570-A1 | COMPOUNDS WITH GLUCOCORTICOID SPARING EFFECTS AND USES THEREOF | NR3C1, NR3C2, NR5A1 | PI4KA 1925/4885PI4K2B 1841/4885PI4K2A 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.